摘要
目的分析miR-338-3p在肾透明细胞癌中的表达及其与凋亡的相关性,为深入探讨miR-338-3p在肾透明细胞癌中的作用机制提供理论基础。方法以曲古抑菌素A(Trichostatin A,TSA)诱导786-O及HK-2,应用荧光定量PCR法检测786-O及HK-2中miR-338-3p的表达水平,采用流式细胞术检测786-O及HK-2的细胞凋亡率。结果786-O细胞中miR-338-3p相对表达量显著低于HK-2细胞(P<0.01);786-O细胞中miR-338-3p的表达水平随着TSA浓度的升高而升高,HK-2细胞miR-338-3p的表达水平随着TSA浓度的升高而下调;786-O及HK-2的凋亡率均随着TSA浓度升高而升高。以不同浓度TSA诱导时,786-O细胞的凋亡率与miR-338-3p表达水平呈显著正相关,相关系数为0.985(P<0.01)。HK-2细胞凋亡率与miR-338-3p表达水平无显著相关性(P>0.05)。结论 miR-338-3p在肾透明细胞癌细胞中的表达水平显著低于正常细胞,肾透明细胞癌细胞的凋亡率与miR-338-3p表达水平显著正相关;miR-338-3p可能参与肾细胞癌的发生、发展,提示其具有作为肾细胞癌诊断和治疗靶点的潜能。
Objective To analyze the expression of miR-338-3p in clear cell renal cell carcinoma and its correlation with apoptosis,and to provide a theoretical basis for further study of the mechanism of miR-338-3p in clear cell renal cell carci- noma. Methods To induced 786-0 and HK-2 with different concentrations of TSA, quantifieational real-time PCR （qRT- PCR） was used to detect the expression level of miR-338-3p in 786-0 and HK-2,flow cytometry was used to detect the apop- totic rates of 786-0 and HK-2. Results The relative expression of miR-338-3p in 786-0 ceils was significantly lower than that in HK-2 cells（P 〈0.01 ） ;The expression level of miR-338-3p in 786-0 increased with the increase of TSA concentration,and the expression level of miR-338-3p in HK-2 decreased with the increase of TSA concentration ;The apoptosis rates of 786-0 and HK-2 increased with the increase of TSA concentration. When induced with different concentration of TSA, the apoptosis rate of 786-0 ceils was positively correlated with the expression level of miR-338-3p, the correlation coefficient was 0.985 （P 〈 0.01）. HK-2 apoptosis rate and miR-338-3p expression level was not significantly correlated （ P 〉 0.05）. Conclusion The expression level of miR-338-3p in clear cell renal cell carcinoma was significantly lower than that in normal cells,the apoptotic rate of clear cell renal cell carcinoma was significantly correlated with the expression level of miR-338-3p;miR-338-3p may be involved in the development and progression of renal cell carcinoma, suggesting that it has the potential to be used as a diagnos- tic and therapeutic target for renal cell carcinoma.
出处
《临床合理用药杂志》
2017年第34期20-22,共3页
Chinese Journal of Clinical Rational Drug Use
